Johnson & Johnson Analyst: 3 Takeaways On Opioid Litigation

With Johnson & Johnson (NYSE: JNJ) facing off against the state of Oklahoma this week over its potential responsibility for the opioid crisis in that state, BMO Capital Markets issued a report Thursday on the company's thinking as it heads to court.

The Analyst

Joanne Wuensch maintained an Outperform rating on Johnson & Johnson with a $157 price target.

The Thesis

An Oklahoma case allges that Johnson & Johnson it has some responsibility for the opioid epidemic, Wuensch said in a Thursday note. (See her track record here.)

After a $270-million settlement by Purdue in March and an -million settlement by Teva Pharmaceutical Industries Ltd (NYSE: TEVA) in May, J&J is the remaining defendant in the case, relative to the sales of its Duragesic transdermal patch and the drug Nucynta.

The analyst highlighted the following takeaways following a conversation with the company regarding the litigation:

• J&J feels strongly that its products were specifically designed to limit abuse.

• Since the case is heard by a judge and not a jury, a hearing could take two to four weeks, with completion in two months.

• Litigation is a common occurrence in the health care sector that takes significant time to resolve, and often headlines are worse than reality.

J&J is now part of federal multidistrict litigation that bundles opioid cases for over 20 companies that's set to begin in late October, Wuensch said.

The Price Action

Johnson & Johnson shares were trading higher by 0.72 percent at $132.30.

Related Links:

Johnson & Johnson Analysts Laud Accelerating Pharma Business

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Photo by Dustin Blitchok.

Latest Ratings for JNJ

May 2019		Maintains		Outperform
Apr 2019		Maintains	Outperform	Outperform
Apr 2019		Maintains	Outperform	Outperform

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

See more from Benzinga

• The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

• Johnson & Johnson Analysts Laud Accelerating Pharma Business

• Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.